Welcome to our dedicated page for Lilly Eli & Co news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Lilly Eli & Co stock.
Eli Lilly and Company (NYSE: LLY) generates frequent news across cardiometabolic health, oncology, immunology, obesity and manufacturing expansion. This page aggregates recent press releases and third-party coverage so readers can follow how Lilly’s medicines, clinical programs and corporate actions are evolving over time.
Recent updates show Lilly reporting Phase 3 results for multiple late-stage assets. In obesity and cardiometabolic health, the company has shared topline data from ATTAIN-MAINTAIN, a Phase 3 trial of orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for weight maintenance after prior treatment with injectable incretin therapies. Lilly has also reported results from TRIUMPH-4, a Phase 3 trial of retatrutide, an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight and knee osteoarthritis, with co-primary endpoints in weight loss and pain reduction.
In immunology, Lilly has announced positive topline results from the TOGETHER-PsA Phase 3b trial, which evaluated concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) versus Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition. The company reports that the combination met the primary endpoint and all key secondary endpoints, supporting an integrated approach to treating psoriatic arthritis and obesity.
Oncology news includes updated EMBER-3 data for Inluriyo (imlunestrant) as monotherapy and in combination with Verzenio (abemaciclib) in ER-positive, HER2-negative advanced breast cancer, and Phase 3 BRUIN CLL-313 results showing that Jaypirca (pirtobrutinib) significantly reduced the risk of progression or death versus chemoimmunotherapy in treatment-naïve CLL/SLL without 17p deletions.
Corporate and strategic news items cover Lilly’s planned acquisition of Ventyx Biosciences, completion of the Adverum Biotechnologies tender offer, a strategic collaboration with Aktis Oncology, and a major manufacturing investment in a new active pharmaceutical ingredient facility in Huntsville, Alabama. Investors and observers can use this news feed to monitor clinical milestones, regulatory submissions, acquisitions, collaborations, financing activities and manufacturing expansions related to LLY.
Eli Lilly and Company (NYSE: LLY) announced its participation in the 2022 European Society for Medical Oncology (ESMO) Congress, scheduled for September 9-13, 2022. The company will present key data on its drugs Verzenio® (abemaciclib) and Retevmo® (selpercatinib). Highlights include interim overall survival results from the Phase 3 MONARCH 3 study for Verzenio in advanced breast cancer, and long-term follow-up data for Retevmo in medullary thyroid cancer and non-small cell lung cancer. These presentations aim to advance understanding and treatment options in oncology.
Eli Lilly (NYSE: LLY) will attend the Morgan Stanley 20th Annual Global Healthcare Conference on Sept. 13, 2022. Anat Ashkenazi, the company's CFO, will take part in a fireside chat at 11:10 a.m. Eastern time.
A live audio webcast of the event will be accessible on Lilly's Investor website, with a replay available for 90 days. Lilly has a legacy of nearly 150 years in pioneering medicines that improve lives, helping over 47 million people globally, and is focused on addressing major health challenges.
Eli Lilly and Company (NYSE: LLY) will participate in Citi's 17th Annual BioPharma Conference on September 7, 2022. Daniel Skovronsky, M.D., Ph.D., the company's chief scientific and medical officer, will engage in a fireside chat at 3:30 p.m. ET. A live audio webcast will be accessible via Lilly's Investor website, with a replay available for approximately 90 days.
For over 150 years, Lilly has focused on creating innovative medicines, helping over 47 million people globally. Their ongoing research aims to address critical health challenges, including diabetes, obesity, and Alzheimer's disease.
Eli Lilly and Company (NYSE: LLY) announces key leadership changes as Stephen Fry, Senior Vice President of Human Resources and Diversity, will retire at the end of 2022 after over 35 years with the company. Eric Dozier, currently Vice President and Chief Commercial Officer for Loxo@Lilly, is promoted to succeed Fry and will focus on enhancing Lilly's human resources and diversity strategy. Winselow Tucker will join as Senior Vice President and Chief Commercial Officer for Loxo@Lilly, bringing extensive experience from Bristol Myers Squibb, Novartis, and Celgene to drive growth in the oncology and hematology sectors.
Eli Lilly and Company (LLY) announced the launch of a new citrate-free formulation of Taltz (ixekizumab) injection, approved by the FDA in May 2022. This formulation aims to reduce injection site pain by 86% compared to the original. Taltz is prescribed for moderate to severe plaque psoriasis and other autoimmune conditions. Over 130,000 patients have been treated with Taltz in the U.S. since its approval in 2016. The new formulation has shown consistent safety profiles, and existing patients will not require new prescriptions during the transition period.
Eli Lilly and Company (NYSE: LLY) has rescheduled its second-quarter 2022 financial results investor conference call to 10 a.m. Eastern time due to technical difficulties. Investors and the public can access a live webcast through Lilly's website, with a replay available afterward. The company emphasizes its commitment to advancing healthcare solutions and improving patient access to medicines globally.
Eli Lilly and Company (LLY) reported Q2 2022 revenue of $6.49 billion, a 4% decline year-over-year, primarily due to lower realized prices and Alimta's generic competition. Excluding these factors, core revenue grew 6%. Key growth products, including Trulicity and Verzenio, surged 20%, comprising 67% of total revenue. EPS fell 31% to $1.05 (reported) and 32% to $1.25 (non-GAAP). The company updated its 2022 EPS guidance to $6.96-$7.11 (reported) and $7.90-$8.05 (non-GAAP). Notable advancements included the U.S. launch of Mounjaro and FDA approvals for donanemab and pirtobrutinib.
Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2022 financial results on Aug. 4, 2022, at 9 a.m. Eastern time. The company will hold a conference call to discuss its financial performance, accessible via a live webcast on Lilly's website. This event reflects Lilly's ongoing commitment to transparency with its investors and stakeholders, providing details of its business performance and future outlook.
Investors can find further information on the upcoming call and access details through Lilly's investor relations site.
Eli Lilly (NYSE: LLY) announced a modified agreement with the U.S. government to provide an additional 150,000 doses of the monoclonal antibody bebtelovimab for approximately $275 million. This supply is expected to meet the demand until late August 2022. Bebtelovimab continues to neutralize known variants, including the Omicron variants BA.2.12.1 and BA.4/BA.5. The deal is projected to generate approximately $0.08 in EPS. An option for an additional 350,000 doses exists, exercisable by September 14, 2022.
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend of $0.98 per share for the third quarter of 2022. This dividend is payable on Sept. 9, 2022 to shareholders of record as of Aug. 15, 2022. Eli Lilly, known for its significant contributions to healthcare, continues to work on advancements in various medical fields, including diabetes, obesity, and Alzheimer's disease. The company emphasizes its commitment to innovative clinical trials and the accessibility of its medicines.